Downloads

• 1. Ponader S and Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol, 2014; 32: 1830-1839. • 2. Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost, 2017. • 3. Futatani T, Watanabe C, Baba Y, Tsukada S, and Ochs HD. Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol, 2001; 114: 141-149. • 4. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, and Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood, 2006; 108: 2596-2603. • 5. Atkinson BT, Ellmeier W, and Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood, 2003; 102: 3592-3599. • 6. Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol, 2017. • 7. Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 2017. • 8. Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med, 2016; 374: 323-332. • 9. Bye AP, Unsworth AJ, Vaiyapuri S, et al. Ibrutinib Inhibits Platelet Integrin alphaIIbbeta3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen. Arterioscler Thromb Vasc Biol, 2015; 35: 2326-2335. • 10. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia, 2015; 29: 783-787. • 11. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood, 2014; 124: 3991-3995. • 12. Moroi M, Jung SM, Okuma M, and Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest, 1989; 84: 1440-1445. • 13. Takahashi H and Moroi M. Antibody against platelet membrane glycoprotein VI in a patient with systemic lupus erythematosus. Am J Hematol, 2001; 67: 262-267. • 14. Kojima H, Moroi M, Jung SM, et al. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost, 2006; 4: 2433-2442. • 15. Lopez JA, Andrews RK, Afshar-Kharghan V, and Berndt MC. Bernard-Soulier syndrome. Blood, 1998; 91: 4397-4418. • 16. Law DA, DeGuzman FR, Heiser P, et al. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature, 1999; 401: 808-811. • 17. Senis YA, Mazharian A, and Mori J. Src family kinases: at the forefront of platelet activation. Blood, 2014; 124: 2013-2024. • 18. Wahl MI, Fluckiger AC, Kato RM, et al. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors. Proc Natl Acad Sci U S A, 1997; 94: 11526-11533. • 19. Li Z, Wahl MI, Eguinoa A, et al. Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci U S A, 1997; 94: 13820-13825. • 20. Quintas-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer, 2009; 115: 2482-2490. • 21. Quintas-Cardama A, Han X, Kantarjian H, and Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood, 2009; 114: 261-263. • 22. Gratacap MP, Martin V, Valera MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood, 2009; 114: 1884-1892. • 23. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015; 125: 2497-2506. • 24. Kazianka L, Drucker C, Skrabs C, et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia, 2017; 31: 1117-1122. • 25. Seiter K, Stiefel MF, Barrientos J, et al. Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. Stem Cell Investig, 2016; 3: 27. • 26. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet, 2016; 387: 2605-2613. • 27. Desborough MJ, Oakland KA, Landoni G, et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost, 2017; 15: 263-272. • 28. American Society of Anesthesiologists Task Force on Perioperative Blood M. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology, 2015; 122: 241-275. • 29. Frontera JA, Lewin JJ, 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care, 2016; 24: 6-46. • 30. Svensson PJ, Bergqvist PB, Juul KV, and Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev, 2014; 28: 95-102. • 31. Desborough MJ, Smethurst PA, Estcourt LJ, and Stanworth SJ. Alternatives to allogeneic platelet transfusion. Br J Haematol, 2016; 175: 381-392. • 32. Lordkipanidze M, Lowe GC, Kirkby NS, et al. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood, 2014; 123: e11-22. • 33. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A, 2010; 107: 13075-13080. • 34. Dunster JL, Mazet F, Fry MJ, Gibbins JM, and Tindall MJ. Regulation of Early Steps of GPVI Signal Transduction by Phosphatases: A Systems Biology Approach. PLoS Comput Biol, 2015; 11: e1004589. • 35. Nore BF, Mattsson PT, Antonsson P, et al. Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases. Biochim Biophys Acta, 2003; 1645: 123-132. • 36. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol, 2013; 31: 88-94. • 37. Qiu Y and Kung HJ. Signaling network of the Btk family kinases. Oncogene, 2000; 19: 5651-5661. • 38. Burkhart JM, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood, 2012; 120: e73-82. • 39. Kim YJ, Sekiya F, Poulin B, Bae YS, and Rhee SG. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol, 2004; 24: 9986-9999. • 40. Colucci G, Stutz M, Rochat S, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood, 2014; 123: 1905-1916.